Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd Class ASSE: 600671

"Hangzhou Tianmushan Pharmaceutical Enterprise Co., Ltd."Announcement on Provision for Credit Impairment and Asset Impairment for the First Half of 2026

Aug 28, 2026 · Issued by Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd Class A via Shanghai Stock Exchange

Announcement on Provision for Credit Impairment and Asset Impairment for the First Half of 2026

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis

Earlier from Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd Class A

"Hangzhou Tianmushan Pharmaceutical Enterprise Co., Ltd."Announcement on the Public Solicitation of Transferees for the Controlling Shareholder's Proposed Transfer of Certain Shares of the Company through Public Solicitation and AgreementJul 23
"Hangzhou Tianmushan Pharmaceutical Enterprise Co., Ltd."Indicative Announcement on Proposed Transfer of Part of Company's Shares by Controlling Shareholder through Public Solicitation and Possible Change in ControlJul 14
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026Jun 30
Announcement on Reply to Letter of Supervision and Inquiry of 2025 Annual ReportJun 19

All Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd Class A news releases